EndoTODAY | EndoATLAS | OPD

Parasite | Eso | Sto | Cancer | ESD

Boxim | DEX | Sono | Schedule

Home | Recent | Blog | Links

EndoTODAY ³»½Ã°æ ±³½Ç


[Helicobacter pylori negative gastric cancer (HPNGC). Ç︮ÄÚ¹ÚÅÍ À½¼º À§¾Ï] - ðû

Á¶Á÷°Ë»ç´Â signet ring cell carcinoma¿´À¸¸ç ESD·Î Ä¡·áÇÏ¿´°í 5mm lamina propria cancer¿´À½.

1. 2017³â ÇÑÀÏ ³»½Ã°æÇÐȸ. Sugano ¼±»ý´Ô Á¶Âù °­ÀÇ

2. 2017³â ³»½Ã°æÇÐȸ ¼¼¹Ì³ª. ¼Û°æÈ£ ±³¼ö´Ô °­ÀÇ

3. 2015³â Digest Endosc ¸®ºä

4. À̼±¿µ ±³¼ö´Ô 2020³â ¸®ºä¿Í 2021³â °­ÀÇ

5. FAQs

6. References


1. 2017³â ÇÑÀÏ ³»½Ã°æÇÐȸ Sugano ¼±»ý´Ô Á¶Âù °­ÀÇ

ÇÐȸ ¶§¸¶´Ù breakfast sessionÀº ²À Âü¼®ÇÏ´Â ÆíÀÔ´Ï´Ù. ±×·±µ¥ À̹ø ÇÐȸ¸¸Å­ breakfast sessionÀÌ ´ë¼ºÈ²À» ÀÌ·é °ÍÀº º» ÀûÀÌ ¾ø½À´Ï´Ù. ´ë´ÜÇÑ ½Ã°£À̾ú½À´Ï´Ù.


Hp negative gastric cancer´Â µÎ Á¾·ù°¡ ÀÖ½À´Ï´Ù. (1) GC arising in the Hp-uninfected mucosa (familial GC, EBV-associated GC, autoimmune gastritis-associated GC, sporadic cancer with unknown causes)¿Í (2) GC arising in the mucosa infected with Hp in the past (spontaneous disappearance - advanced atrophy/IM, post-eradication therapy)

Yamamoto Y. Digest Endosc 2015

Hp À½¼ºÀ» Á¤ÀÇÇÏ´Â °ÍÀº °£´ÜÇÑ ÀÏÀÌ ¾Æ´Õ´Ï´Ù. Current infection »Ó¸¸ ¾Æ´Ï¶ó past infectionµµ ÀÖÀ¸¸ç ¸ðµç °Ë»ç°¡ ÀÏÁ¤ÇÑ Á¤µµÀÇ false negative¸¦ °¡Áö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ´Ù¸¥ ¸ðµç °Ë»ç¿¡¼­ À½¼ºÀÌ°í ´ÜÁö CagA Ç×ü¸¸ ¾ç¼ºÀÎ °æ¿ìµµ ÀÖ½À´Ï´Ù.

Ye W. Scand J Gastroenterol 2005

Hp °¨¿°ÀÌ Çѹøµµ ¾ø¾ú´ø ȯÀÚÀÇ À§¾ÏÀº ÃÖ±Ù ¸®ºä¿¡¼­´Â 1.7% Á¤µµ¿´½À´Ï´Ù (Yamamoto Y. Digest Endosc 2015). Genuine Hp - gastric cancer´Â 1% ¹Ì¸¸ÀÏ °ÍÀ¸·Î »ý°¢µË´Ï´Ù. ÀÌ ºñÀ²Àº °Ë»ç¸¦ ¾ó¸¶³ª strictÇÏ°Ô Çϴ°¡¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ¿¹¸¦ µé¾î CagA Ç×ü °Ë»ç¸¦ ÇÏ¸é ±âÁ¸ÀÇ ELISA·Î ¹ß°ßÇÏÁö ¸øÇÏ¿´´ø °ú°Å °¨¿°ÀÇ Áõ°Å¸¦ ãÀ» ¼ö ÀÖ½À´Ï´Ù. CagA Ç×ü°¡ ´Ù¸¥ Ç×ü¿¡ ºñÇÏ¿© ¿À·¡ Áö¼ÓµÇ±â ¶§¹®ÀÔ´Ï´Ù.

FAP ȯÀÚ¿¡¼­µµ °£È¤ À§ Á¾¾çÀÌ ¹ß»ýÇÕ´Ï´Ù.

Nakamura K. Endoscopy International Open 2017

Nakamura K. Endoscopy International Open 2017

Nakamura K. Endoscopy International Open 2017

Pyloric gland adenoma´Â misnomerÀÔ´Ï´Ù (Hashimoto. Histopathology 2015). ¿Ö³ÄÇϸé À̸§°ú ´Þ¸® fundic gland¿¡¼­ ¹ß»ýÇϱ⠶§¹®ÀÔ´Ï´Ù. Background gastric mucosa´Â atrophicÇÑ °æ¿ì°¡ ¸¹Àºµ¥ ƯÈ÷ autoimmune atrophy¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù (Vieth M. Virchows Arch 2003).

Vieth M. Virchows Arch 2003

Vieth M. Virchows Arch 2003

EBV positive gastric cancer (Gastroenterology 2009;137:824-33, Fukayamo M. Pathology International 2010:60:337-50, Wu Gastroenterology 2000;118:1031-8). ³²ÀÚ¿¡ ¸¹°í lymphoepithelioma-like lesionÀÌ ÀÖ½À´Ï´Ù. ´ëºÎºÐ Hp °¨¿°ÀÌ ÀÖ½À´Ï´Ù. EBV°¡ Hp ¾øÀÌ ´Üµ¶À¸·Î À§¾ÏÀ» ÀÏÀ¸Å°´Â °æ¿ì´Â ¸Å¿ì Àû½À´Ï´Ù. EBV-related Hp negative gastric cancer is very rare (Gastroenterology 2015;129:2058-63).

Pernicous anemia°¡ autoimmune gastritis¿Í °°Àº ¸»Àº ¾Æ´Õ´Ï´Ù. Autoimmune gastritisÀÇ ÀϺδ Hp °¨¿°°ú °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. Hp°¨¿°ÀÚ¿¡¼­ parietal cell¿¡ ´ëÇÑ ÀÚ°¡ Ç×ü°¡ ÈçÈ÷ ¹ß°ßµË´Ï´Ù (Helicobacter 2001;6:225-33). Hp negastive autoimmune gastritis¿¡¼­ (type I carcinoid°¡ Á¾Á¾ ¹ß»ýÇÏÁö¸¸) À§¾Ï ¹ß»ýÀº rare ÇÕ´Ï´Ù (Rugge. APT 2012:35:1460). Pyloric gland adenomaÀÇ ÀϺδ autoimmune gastritis¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù (Virchows Arch 2003;442:317-21).

Hp negastive gastric cancer¿¡¼­µµ differentiated typeÀÌ undifferentiated type º¸´Ù ¸¹¾Ò½À´Ï´Ù. ƯÀÌÇÑ Á¡Àº gastric cancer wth fundic gland differentiationÀ» º¸ÀÌ´Â °æ¿ì°¡ ¸¹´Ù´Â °ÍÀÔ´Ï´Ù.

Chiba T. Dig Endosc 2016

GC occurring after eradication of H. pylori´Â ±¹°¡¿¡ µû¶ó ´Ù¸¥ ¾ç»óÀ» º¸ÀÔ´Ï´Ù. ÀϺ»¿¡¼­´Â ´ëºÎºÐ Á¶±âÀ§¾ÏÀ̾ú°í overseas¿¡¼­´Â ÁøÇ༺ À§¾ÏÀÌ ¸¹¾Ò½À´Ï´Ù. ¾Æ¸¶µµ missed cancer¿´À» °¡´É¼ºÀÌ Å®´Ï´Ù. Á¦±ÕÄ¡·á ÈÄ ¹ß»ýÇÏ´Â À§¾ÏÀÇ À§ÇèÀÎÀÚ´Â ¿ª½Ã À§Ã༺ À§¿°ÀÔ´Ï´Ù.

Sugano ±³¼ö´ÔÀÇ ¸ÚÁø °­ÀÇ´Â ¾Æ·¡¿Í °°Àº ½½¶óÀ̵å·Î ³¡³µ½À´Ï´Ù.


2. 2017³â 8¿ù 27ÀÏ ³»½Ã°æÇÐȸ ¼¼¹Ì³ª ¼Û°æÈ£ ±³¼ö´Ô °­ÀÇ

¾ÆÁÖ Â÷ºÐÇÏ°í ¸ÚÁø °­ÀÇ¿´½À´Ï´Ù. ³»½Ã°æ ¼¼¹Ì³ª¶ó´Â Å« ¹«´ë¿¡ ¸ÚÁö°Ô µ¥ºßÇϽŠ°Í ÃàÇÏÇÕ´Ï´Ù. °­ÀÇ ¿ø°íµµ ÁÁ¾Ò½À´Ï´Ù. ¿Å±é´Ï´Ù.


1) ¼­·Ð

Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ®°¡ À§¾ÏÀÇ ÁÖ¿ä ¿øÀÎÀÎ °ÍÀº ÁÖÁöÀÇ »ç½ÇÀÌ´Ù. ƯÈ÷ µÎ °³ÀÇ ÀüÇâÀû ÄÚȣƮ ¿¬±¸µéÀº Ç︮ÄÚ¹ÚÅÍ ÆÄÀϷθ® °¨¿°ÀÚ¿¡ ÇÑÇؼ­¸¸ À§¾ÏÀÌ ¹ß»ýÇÑ´Ù°í °á·ÐÁö¾ú´Ù. ÀÌÈÄ·Î ½ÇÁ¦ ÀÓ»ó¿¡¼­´Â Ç︮ÄÚ¹ÚÅÍÀÇ °¨¿° Áõ°Å°¡ ¾ø´Â Á¤»ó À§ Á¡¸· ¹è°æ¿¡¼­µµ À§ ¼±¾ÏÀ» Áø´ÜÇÑ ¿¹µéÀ» °æÇèÇÏ°Ô µÇ¾ú´Ù. ÀÌ¿¡ ÀϺ», Çѱ¹, ´ë¸¸ µî¿¡¼­ Ç︮ÄÚ¹ÚÅÍ À½¼º À§¾Ï(Helicobacer pylori-negative gastric cancer, HPNGC)¿¡ ´ëÇÑ ¿ªÇÐ ¹× º´¸®ÇÐ ¿¬±¸µéÀÌ ³ª¿À°í ÀÖ´Ù. Ç︮ÄÚ¹ÚÅÍ Á¦±Õ Ä¡·á, º¸´Ù ³ªÀº À§»ýÀ» ÅëÇØ Ç︮ÄÚ¹ÚÅÍ °¨¿° À¯º´·üÀº ²ÙÁØÈ÷ °¨¼ÒÇÏ°í ÀÖ´Ù. 2015³â Ç÷û °Ë»ç¸¦ ÅëÇÑ ¿ì¸®³ª¶ó Ç︮ÄÚ¹ÚÅÍ °¨¿°·üÀº 51.0%À̸ç, 1998³âÀÇ 66.9%¿¡ ºñÇØ Áö¼ÓÀûÀ¸·Î °¨¼ÒµÇ¾úÀ½À» È®ÀÎÇÏ¿´´Ù. Ç︮ÄÚ¹ÚÅÍ °¨¿°·üÀÇ Áö¼ÓÀûÀÎ ÀúÇÏ¿¡ µû¶ó HPNGC¿¡ ´ëÇÑ °ü½ÉÀº »ó´ëÀûÀ¸·Î Áõ°¡ÇÒ ¼ö ÀÖ´Ù. HPNGC¿¡ ´ëÇÑ ¿¬±¸´Â Ç︮ÄÚ¹ÚÅÍ ±Õ ÀÌ¿Ü¿¡ »õ·Î¿î À§¾Ï ¿øÀÎÀ» È®ÀÎÇÏ°Ô µµ¿Í ÁÙ ¼ö ÀÖ´Ù. HPNGC¿¡ ´ëÇÑ ¿¬±¸´Â ¼ÒÈ­±â³»½Ã°æ °ËÁøÀǻ翡°Ô Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÇ Áõ°Å°¡ ¾ø´Â Á¤»ó À§ Á¡¸·À» °ËÁøÇϸ鼭µµ À¯ÀÇÇؼ­ °üÂûÇØ¾ß ºÎÀ§¿Í ÀϺΠƯ¡ÀûÀÎ ¸ð¾çÀÇ À§¾ÏÀÇ ¹ß°ßÀ» À§ÇÑ ³ë·ÂÀ» ±â¿ïÀÌ°Ô µµ¿ÍÁØ´Ù. ÀÓ»ó¿¡¼­ Ç︮ÄÚ¹ÚÅÍ À½¼ºÀÇ °æ¿ì´Â ¼¼ °¡Áö·Î ºÐ·ùÇÒ ¼ö ÀÖ´Ù: 1) Ç︮ÄÚ¹ÚÅÍ °Ë»çÀÇ À§À½¼º, 2) Ç︮ÄÚ¹ÚÅÍ °¨¿° ÈÄ Á¦±Õ »óÅÂ, 3) Ç︮ÄÚ¹ÚÅÍ ºñ°¨¿° »óÅ ÀÌ´Ù. º» °­ÀÇ¿¡¼­´Â Ç︮ÄÚ¹ÚÅÍ ºñ°¨¿°ÀÚ(Helicobacter pylori-naive state)¿¡¼­ ¹ß»ýÇÏ´Â À§¾ÏÀ» ÁÖÁ¦·Î HPNGCÀÇ ¿ªÇÐ, ÀÓ»ó¾ç»ó, ÀϺΠƯ¡ÀûÀÎ ³»½Ã°æ Áø´ÜÀ» Ç︮ÄÚ¹ÚÅÍ ¾ç¼º À§¾Ï°ú ºñ±³ÇÏ¿© ¼Ò°³ÇÏ¿´´Ù.

2)º»·Ð

2-1) HNPGCÀÇ Á¤ÀÇ

Ç︮ÄÚ¹ÚÅÍÀÇ Çö¼º °¨¿° ¹× °ú°Å °¨¿°ÀÌ ¾ø´Â »óŸ¦ ¼±º°Çϱâ À§ÇÑ Áø´Ü±âÁØÀº ¸¹Àº ³­Á¡ÀÌ ÀÖ´Ù. ÀÌ´Â Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÌ ÁøÇàµÊ¿¡ µû¶ó À§ Á¡¸·ÀÇ À§Ãà°ú Àå»óÇÇÈ­»ýÀÌ ¹ß»ýÇÏ°í ÀÌ·Î ÀÎÇØ Ç︮ÄÚ¹ÚÅÍ ±ÕÀÇ Áø´ÜÀ²ÀÌ ±Þ°ÝÇÏ°Ô ÀúÇϵǴ low bacterial loadÀÇ »óÅ·Πº¯È­µÇ±â ¶§¹®ÀÌ´Ù. ¶ÇÇÑ °æµµÀÇ À§ Á¡¸·ÀÇ À§ÃàÀ» ³»½Ã°æ°ú »ý°ËÀ¸·Î Áø´ÜÇÏ´Â µ¥¿¡´Â ÇÑ°è°¡ ÀÖ´Ù. À§ Á¡¸·ÀÇ À§ÃàÀº Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÇ À¯º´·üÀÌ ³ôÀº Áö¿ª¿¡¼­´Â ´ëºÎºÐ Ç︮ÄÚ¹ÚÅÍ °¨¿°¿¡ ÀÇÇÑ °ÍÀ̹ǷÎ, À§ Á¡¸·ÀÇ À§Ãà ¿©ºÎ¸¦ ÆÇ´ÜÇÏ´Â °ÍÀº Ç︮ÄÚ¹ÚÅÍ °¨¿°·ÂÀÌ ¾ø´Â »óÅ (Helicobacter pylori-naive state)¸¦ Áø´ÜÇÏ´Â µ¥ ÀÖ¾î Áß¿äÇÑ ÃàÀÌ´Ù. Yamamoto µîÀº HPNGCÀÇ Áø´Ü ±âÁØÀ» Á¦½ÃÇÏ¿© ³»½Ã°æ, »ý°Ë Á¶Á÷, Ç÷û Pepsinogen assay Áß µÎ °¡Áö ÀÌ»óÀÌ À§ Á¡¸· À§ÃàÀÌ ¾ø´Â »óÅÂÀ̸鼭 ¿ä¼ÒÈ£±â °Ë»ç³ª Ç÷û anti-Helicobacter pylori IgG°¡ À½¼ºÀÎ À§¾Ï ȯÀÚ·Î Á¤ÀÇÇÒ °ÍÀ» ±Ç°íÇÏ¿´´Ù.

(1) ³»½Ã°æ Áø´Ü

Ç︮ÄÚ¹ÚÅÍ °¨¿°·ÂÀÌ ¾ø´Â »óÅÂÀÇ À§ Á¡¸·Àº ¹é»ö±¤ ³»½Ã°æ °üÂû ½Ã Á¡¸·ÀÇ ÁýÇÕ¼¼Á¤¸Æ(collecting venule)ÀÌ À§ Àüü¿¡ À¯ÁöµÇ¾î ÀÖ´Ù. 5 º´¸®ÇÐÀûÀ¸·Î À§ Á¡¸· Ç¥¸é¿¡´Â À§ ¼Ò±¸µé(gastric pits)ÀÌ Á¡ÀÇ ÇüÅ·Πº¸À̸ç, À§ ¼Ò±¸ ÁÖº¯¿¡ ¹Ì¼¼Ç÷°ü°ú À̵éÀÌ ¸ð¿©¼­ º¸´Ù ±½Àº ÁýÇÕ¼¼Á¤¸ÆµéÀÌ ºÐÆ÷ÇÑ´Ù. È®´ë³»½Ã°æÀÌ ¾Æ´Ñ ÀϹÝÀûÀÎ ¹é»ö±¤ ³»½Ã°æÀ¸·Î´Â À§ ¼Ò±¸¿Í ¹Ì¼¼Ç÷°üÀ» °üÂûÇÒ ¼ö ¾øÀ¸³ª ÁýÇÕ¼¼Á¤¸ÆÀº ºÒ°¡»ç¸® ¸ð¾ç°ú Èí»çÇÑ ÇüÅ·Π°üÂûÀÌ °¡´ÉÇÏ´Ù. À§ Á¡¸·ÀÇ ÁýÇÕ¼¼Á¤¸ÆÀ» °üÂûÇϴµ¥ ÀÖ¾î ÁÖÀÇÇØ¾ß ÇÒ °ÍÀº °üÂû ºÎÀ§ÀÇ ¼±Á¤ÀÌ´Ù. ½ÊÀÌÁöÀå ±Ë¾ç, ÀþÀº Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÚÀÇ °æ¿ì À§ »óüºÎ³ª ÁßüºÎ±îÁö ÁýÇÕ¼¼Á¤¸ÆÀÇ Á¤»óÀûÀº ºÐÆ÷°¡ À¯ÁöµÉ ¼ö ÀÖ´Ù. ÀÌ¿¡ ¹ÝÇØ, ÇÏüºÎ ¼Ò¸¸À» Áø´ÜÀÇ ±Ù°Å·Î »ï¾ÒÀ» °æ¿ì¿¡´Â ±ÔÄ¢ÀûÀÎ ÁýÇÕ¼¼Á¤¸ÆÀÇ ºÐÆ÷°¡ À¯ÁöµÇ´Â °æ¿ì °¨¿°ÀÚ°¡ Çϳªµµ ¾ø¾ú°í, ÁýÇÕ¼¼Á¤¸ÆÀÇ ºÐÆ÷°¡ ¾ø¾îÁø °æ¿ìÀÇ 87%¿¡¼­ Ç︮ÄÚ¹ÚÅÍ °¨¿°À» È®ÀÎÇÏ¿´´Ù. À̸¦ ±Ù°Å·Î ÇÏüºÎ ¼Ò¸¸ÀÇ ±ÔÄ¢ÀûÀÎ ÁýÇÕ¼¼Á¤¸ÆÀÇ ºÐÆ÷ÀÇ °üÂûÀº Ç︮ÄÚ¹ÚÅÍ °¨¿°·ÂÀÌ ¾ø´Â »óÅÂÀÇ Áø´Ü¿¡ À¯¿ëÇÏ´Ù. Á¢ÇÕ¼¼Á¤¸ÆÀÇ ºÐÆ÷ ¿Ü¿¡µµ À§ ÀüÁ¤ºÎÀÇ ¼±»óÀÇ ¹ßÀû, fundic gland polypÀÌ À§ °¨¿°·ÂÀÌ ¾ø´Â »óÅÂ¿Í ¿¬°ü¼ºÀÌ ÀÖ´Ù.

ÀÚ°¡¸é¿ª¼º À§¿°°ú ´Þ¸® Ç︮ÄÚ¹ÚÅÍ °¨¿°¿¡ ÀÇÇÑ À§ Á¡¸·ÀÇ À§ÃàÀº ÀüÁ¤ºÎ·ÎºÎÅÍ ½ÃÀ۵Ǵ Ư¡ÀÌ ÀÖ´Ù. Kimura-Takemoto ºÐ·ù¿¡ µû¶ó À§ÃàÀÇ Á¤µµ¸¦ ÆÇÁ¤ÇÏ´Â °ÍÀÌ ÀϹÝÀûÀ̸ç Á¤»ó Á¡¸·°ú À§ÃàµÈ Á¡¸·ÀÇ °æ°èºÎÀ§¸¦ °üÂûÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù. ¿Ö³ÄÇÏ¸é ³»½Ã°æ °Ë»ç Áß ¼Û±â·®ÀÌ °úÇÒ¼ö·Ï À§ ÀúºÎÀÇ Á¡¸·ÇÏ Ç÷°ü»óÀÌ ¶Ñ·ÇÇØ Áú ¼ö Àֱ⠶§¹®ÀÌ´Ù. ÀÌ·± °æ¿ì¿¡ À§ ÀúºÎ Á¡¸·ÀÇ À§ÃàÀ¸·Î È¥µ¿ÇÒ ¿©Áö°¡ ÀÖ´Ù. HPNGC °ü·Ã ¿¬±¸µé¿¡¼­´Â À§Á¡¸·ÀÇ À§ÃàÀÌ ¾ø°Å³ª Kimura-Takemoto classification C-I±îÁö¸¦ Ç︮ÄÚ¹ÚÅÍ °¨¿°·ÂÀÌ ¾ø´Â »óÅÂÀÇ °¡´ÉÇÑ À§ Á¡¸·ÀÇ »óÅ·ΠºÐ·ùÇÏ¿´´Ù.

(2) »ý°Ë Á¶Á÷ Áø´Ü

¾÷µ¥ÀÌÆ®µÈ Sydney system¿¡ ÁØÇÏ¿© Ç¥ÁØÈ­µÈ ´Ù¼¸ ±ºµ¥(üºÎ µÎ ±ºµ¥, °¢ºÎ, ÀüÁ¤ºÎ µÎ ±ºµ¥)ÀÇ À§ Á¡¸· Á¶Á÷À» ºÐ¼®ÇÏ¿© Ç︮ÄÚ¹ÚÅÍÀÇ Çö¼º °¨¿°À̳ª °ú°Å °¨¿°À» ÃßÁ¤ÇÑ´Ù. 7 Sydney systemÀÇ ±âÁØÀ¸·Î À§ ¼±ÀÇ À§Ãà (0Á¡), Àå»óÇÇÈ­»ý (0 ¶Ç´Â 1Á¡), ´ÜÇÙ±¸ ħÀ± (0¶Ç´Â 1Á¡), Áß¼º±¸ ħÀ± (0Á¡), H. pylori ¹Ðµµ (0Á¡)ÀÎ °æ¿ì¿¡ Á¡¸·ÀÇ À§ÃàÀÌ ¾ø°í, Ç︮ÄÚ¹ÚÅÍÀÇ °¨¿°·ÂÀÌ ¾ø´Â °ÍÀ¸·Î ÆÇ´ÜÇÒ ¼ö ÀÖ´Ù.

(3) Pepsinogen assay À§ ¼±ÀÇ chief cell, mucus neck cellÀº pepsinogenÀ» »ý¼ºÇÑ´Ù. À§ Á¡¸·ÀÇ À§ÃàÀÌ ±¤¹üÀ§ÇØÁú¼ö·Ï Ç÷ûÀÇ pepsinogenÀÇ ¾ç»óÀº º¯È­ÇÑ´Ù. Pepsinogen IÀº À§ ÀúºÎ¿¡¼­¸¸ »ý¼ºµÇ´Â ¹Ý¸é, Pepsinogen II´Â Àüü À§ Á¶Á÷°ú ½ÊÀÌÁöÀå ±¸ºÎ¿¡¼­ »ý¼ºµÈ´Ù. À§ Á¡¸·ÀÇ À§ÃàÀÌ ¾ø´Â °æ¿ì¿¡´Â Ç÷û Pepsinogen I >70ng/mL, Pepsinogen I/II ratio >3.0À¸·Î À¯ÁöµÇ°í À§ Á¡¸·ÀÇ À§ÃàÀÌ ÀúºÎ±îÁö ±¤¹üÀ§ÇØÁö¸é Pepsinogen IÀÇ ÀúÇÏ°¡ µÎµå·¯Áö¸é¼­ Pepsinogen IÀÇ ÀúÇÏ ¹× Pepsinogen I/II ratioÀÇ ÀúÇÏ°¡ ½ÉÈ­µÈ´Ù. ÀÌ·¯ÇÑ Pepsinogen assayÀÇ °á°ú À§ Á¡¸·ÀÇ À§ÃàÀÌ ¾ø´Â °ÍÀ¸·Î ³ª¿Ã °æ¿ì À½¼º¿¹Ãøµµ 99%ÀÌ»óÀ¸·Î Á¤»ó À§ Á¡¸·À¸·Î Áø´ÜÇÒ ¼ö ÀÖ´Ù. ¹Ý¸é Ç︮ÄÚ¹ÚÅÍ °¨¿°ÀÚ°¡ Á¦±Õ Ä¡·á¸¦ ¹ÞÀº µÚ 12°³¿ùÀÌ»ó °æ°ú ½Ã¿¡´Â »ó´ç ºÎºÐ °¨¿°·ÂÀÌ ¾ø´Â Á¤»óÀÎÀÇ ¼öÄ¡¿Í Â÷ÀÌ°¡ ¾ø¾îÁö¸é¼­ Á¤»óÈ­ µÇ±âµµ ÇÑ´Ù. ±×·¯¹Ç·Î, Ç÷û PepsinogenÀÇ Çؼ®À» ÇÒ °æ¿ì¿¡´Â Á¦±Õ Ä¡·á·ÂÀ» °í·ÁÇؼ­ À§ Á¡¸·ÀÇ À§ÃàÀ» ÆÇ´ÜÇØ¾ß ÇÑ´Ù.

2-2) ¿ªÇÐ ¿¬±¸

Kato µîÀº ÀϺ»ÀÎ À§¾Ï ȯÀÚ 748¸íÀ» ´ë»óÀ¸·Î Ç÷û Ç︮ÄÚ¹ÚÅÍ Ç×ü¿Í Pepsinogen assayÀ» ÅëÇؼ­ HPNGCÀÇ ºñÀ²À» °è»êÇÏ¿´´Ù. ´ë»óÀÚÀÇ 14.2%¿¡¼­ Ç÷û Ç×ü°¡ À½¼ºÀ̾ú°í 2.0%ÀÇ È¯ÀÚ°¡ Pepsinogen assay À§Ãà À½¼ºÀ̾ú´Ù. ´ë»óÀÚÀÇ 3.6%´Â Ç÷û Ç︮ÄÚ¹ÚÅÍ Ç×ü À½¼ºÀ̸鼭 µ¿½Ã¿¡ ±¤¹üÀ§ÇÑ À§ Á¡¸· À§Ãà ¾ç¼ºÀ̾ú´Ù(Pepsinogen I <30ng/mL, Pepsinogen I/II ratio <2.0). ±×·¯¹Ç·Î 3.6%ÀÇ Ç÷û À½¼º ȯÀÚ´Â ½ÉÇÑ À§Ã༺ À§¿°À¸·Î ÀÎÇÑ Ç︮ÄÚ¹ÚÅÍ ±ÕÀÇ ÀÚ¿¬ ¼Ò½Ç°ú Ç×ü Á¤»óÈ­·Î ºÐ·ùÇÒ ¼ö ÀÖ¾ú´Ù. À̸¦ ±Ù°Å·Î ÇØ´ç º´¿øÀÇ HPNGCÀÇ ºñÀ²Àº ÃÖ¼Ò 2.0%, ÃÖ´ë 10.6%(14.2% »©±â 3.6%)·Î »êÁ¤ÇÏ¿´´Ù. Matsuo µîÀº ÀϺ»ÀÎ À§¾Ï ȯÀÚ 3161¸íÀ» ´ë»óÀ¸·Î Ç÷û Ç︮ÄÚ¹ÚÅÍ Ç×ü, »ý°Ë °á°ú, ³»½Ã°æ Áø´Ü, ¿ä¼ÒÈ£±â°Ë»ç, RUT µîÀ» ¼øÂ÷ÀûÀ¸·Î ½ÃÇàÇÏ¿© ÃÖÁ¾ÀûÀ¸·Î 0.66%ÀÇ ³·Àº ºñÀ²À» È®ÀÎÇÏ¿´´Ù. ¸Å¿ì ¾ö°ÝÇÑ HPNGCÀÇ ±âÁØ(³»½Ã°æ Áø´Ü, »ý°Ë Áø´Ü, Pepsinogen assay, Ç÷û Ç︮ÄÚ¹ÚÅÍ Ç×ü, ¿ä¼ÒÈ£±â°Ë»ç, RUT, ´ëº¯ Ç×ü, Á¦±Õ Ä¡·á·ÂÀ» ¸ðµÎ °í·Á)À» Àû¿ëÇÑ µÎ °³ÀÇ ÀϺ» ¿ªÇÐ ¿¬±¸ÀÇ °á°ú·Î´Â °¢°¢ 0.42%¿Í 2.3%ÀÇ ºñÀ²À» È®ÀÎÇÏ¿´´Ù. À± µîÀº Çѱ¹ÀÎ À§¾Ï ȯÀÚ 627¸íÀ» ºÐ¼®ÇÏ¿© 5.4%ÀÇ ºñ±³Àû ³ôÀº HPNGCÀÇ ºñÀ²À» º¸°íÇÏ¿´´Ù. ÀÌ´Â ÀϺ»ÀÇ º¸°íµé¿¡ ºñÇØ ºñ±³Àû ³ôÀº ºñÀ²ÀÌ´Ù. ³ôÀº HPNGCÀÇ ÀÌÀ¯ Áß Çϳª·Î Pepsinogen assay¸¦ ÅëÇؼ­ ±¤¹üÀ§ÇÑ À§Ã༺ À§¿° ȯÀڵ鸸À» ¹èÁ¦ÇÏ°í °æµµ ¹× Áߵ À§Ã༺ À§¿° ȯÀÚµéÀº Æ÷ÇÔÇÑ ±âÁØÀÌ ÀÖ´Ù. Ç︮ÄÚ¹ÚÅÍ °¨¿° À¯º´·üÀÌ ³·Àº ³ª¶óµéÀÇ HPNGCÀÇ ºñÀ²Àº 13.8%~24.6%·Î ºñ±³Àû ³ôÀ½À» ¾Ë ¼ö ÀÖ´Ù.

ÀÌ»óÀ» Á¤¸®Çϸé, Ç︮ÄÚ¹ÚÅÍ °¨¿°·üÀÌ ³ôÀº ³ª¶ó¿¡¼­´Â 1% ¾ÈÆÆ, °¨¿°·üÀÌ ³·Àº ³ª¶ó¿¡¼­´Â 20% ¾ÈÆÆÀÇ HPNGCÀÇ À¯º´·üÀ» È®ÀÎÇÒ ¼ö ÀÖ´Ù.

2-3) ÀÓ»óÀû Ư¡

HPNGCÀÇ Á¤ÀÇ°¡ ¿¬±¸¸¶´Ù »óÀÌÇÏ°í, ÄÉÀ̽º ¼öµµ ¸¹Áö ¾ÊÀº ´ÜÀÏ ±â°ü ºÐ¼®ÀÇ ÇÑ°è·Î ÀÎÇØ HPNGCÀÇ ÀϹÝÀûÀÎ ÀÓ»óÀûÀΠƯ¡À» ±â¼úÇϱâ´Â ¾î·Æ´Ù. º¸°íµÈ ¿¬±¸µéÀÇ ¸¹Àº ¼ö¿¡¼­ 60¼¼ ¹Ì¸¸ÀÇ ºñ±³Àû ÀþÀº ¿¬·ÉÀ̶ó´Â Á¡, ³²³à ¼ººñ°¡ 0.7~2.5 Á¤µµ·Î ºñ±³Àû ¿©¼º ȯÀÚ°¡ ¸¹Àº Á¡, ¹ÌºÐÈ­Çü ¾ÏÀÇ ºñÀ²ÀÌ 42.9~100%·Î ³ôÀº Á¡Àº ÁÖÁöÇÒ ¸¸ÇÏ´Ù. ±ÙÀ§ºÎ ¾ÏÀÇ ºñÀ²Àº 25% Á¤µµ·Î¼­, Ç︮ÄÚ¹ÚÅÍ ¾ç¼ºÀÎ À§¾Ï¿¡ ºñÇØ 13% °¡·® ³ô´Ù.

³»½Ã°æ Áø´ÜÀÇ Æ¯Â¡Àº Chief cell predominant typeÀÇ À§¾ÏÀÇ °æ¿ì ºñ±³Àû Ư¡ÀûÀÌ´Ù. Á¡¸·ÇÏÁ¾¾çÀÇ ÇüÅÂ, Ȳ¹é »öÁ¶, º´º¯ ³» ¸ð¼¼Ç÷°ü»óÀÇ µÎµå·¯Áø Ç÷°üÀÇ ¸ð¾ç µî ºñ±³Àû Ưº°ÇÑ ¸ð¾çÀ» ¶è °æ¿ì°¡ ¸¹´Ù(Èļú). HPNGC°¡ Ç︮ÄÚ¹ÚÅÍ ¾ç¼º À§¾Ï¿¡ ºñÇØ ¿¹ÈÄ°¡ ³ª»Ú´Ù´Â º¸°íµéÀÌ ÀÖ´Ù. Stage IIÀÌÇÏ, Stage IIIÀÌÇÏ, ¸ðµç º´±â¿¡¼­ HPNGCÀÇ ¿¹ÈÄ°¡ Ç︮ÄÚ¹ÚÅÍ ¾ç¼º À§¾Ï¿¡ ºñÇØ ³ª»¦´Ù. ÀÌ·¯ÇÑ °æÇâÀº ´Ù¸¥ ³ª»Û ¿¹ÈÄÀÎÀÚµéÀ» º¸Á¤ÇÏ°í¼­µµ À¯ÁöµÇ¾î, Helicobacter pylori-naive state ÀÚü°¡ À§¾ÏÀÇ µ¶¸³ÀûÀÎ ³ª»Û ¿¹ÈÄÀÎÀÚ·Î º¸°íÇÏ¿´´Ù. ¾Ï ÀüÀÌ¿Í °ü°è ÀÖ´Â E-Cadherin, microsatellite instability, matrix metalloproteinase µîÀÌ ÀÌ·¯ÇÑ ³ª»Û ¿¹ÈÄ¿Í ¿¬°üÀÌ ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤ÇÏ°í ÀÖ´Ù. ¹Ý¸é Chief cell predominant typeÀÇ À§¾ÏÀº Ä¡·á ¾øÀÌ Æò±Õ 58°³¿ù ÀÌ»ó °æ°ú °üÂûÇÑ 11¿¹(ÀÌÁß HPNGC´Â 3¿¹) ¸ðµÎ¿¡¼­ ÁøÇàÀÌ ¾ø¾ú´Ù. ÁøÇ༺ À§¾ÏÀ¸·Î Áø´ÜµÈ fundic gland typeÀÇ À§¾ÏÀº Áõ·Ê º¸°í ¼öÁØÀÌ´Ù.

2-4) HPNGCÀÇ ´Ù¾çÇÑ Çüŵé

(1) Lymphoepithelioma-like carcinoma

Epstein-Barr virus °¨¿°Àº ºñÀεΠ¸²ÇÁ»óÇÇÁ¾°ú À¯»çÇÑ ÇüÅÂÀÇ À§¾ÏÀ» À¯¹ßÇÒ ¼ö ÀÖ´Ù(lymphoepithelioma-like carcinoma, LELC). 24 ´ëºÎºÐÀÇ EBV ¾ç¼º À§¾ÏÀº À§Ã༺ À§¿°°ú µ¿¹ÝµÈ »óÅÂÀ̳ª Ç︮ÄÚ¹ÚÅÍ °¨¿°À²Àº ºñ±³Àû ³·´Ù. À§ ±ÙÀ§ºÎÀÇ ¹ÌºÐÈ­Çü ¼±¾ÏÀÇ ÇüÅ·ΠÁø´ÜµÇ´Â Ư¡ÀÌ ÀÖ´Ù. ¿ì¸®³ª¶óÀÇ ¿¬±¸¿¡¼­µµ ÀÌ·¯ÇÑ °æÇâÀº À¯ÁöµÇ¾ú°í, LELC´Â µ¶¸³ÀûÀÎ ¿¹ÈÄÀÎÀÚ´Â ¾Æ´Ï¾ú´Ù.

(2) Germline mutation (CDH1 gene mutation)

Diffuse-type gastric cancerÀÇ ÁÖ¿ä º´ÀÎ Áß ÇϳªÀÎ CDH1 À¯ÀüÀÚ º¯ÀÌ´Â »óÇǼ¼Æ÷ À¯Âø ¹°ÁúÀÎ E-CadherinÀ» ÄÚµù Çϴµ¥ ÀÌ»óÀÌ ÀÖ´Ù. 28 À¯ÀüÀû ¹Ì¸¸Çü À§¾ÏÀÇ È¯Àڵ鿡°Ô¼­µµ CDH1 À¯ÀüÀÚÀÇ germline mutationÀ» È®ÀÎÇÒ ¼ö ÀÖ´Ù. Germline CDH1 mutationÀÌ Àִ ȯÀÚµéÀº ÀÏ»ý¿¡ À§¾ÏÀÌ »ý±æ À§ÇèÀÌ 70%ÀÌ»ó, À¯¹æ¾ÏÀÌ »ý±æ À§ÇèÀÌ 40%ÀÌ»óÀÌ´Ù. À¯ÀüÀû ¹Ì¸¸Çü À§¾ÏÀÇ °æ¿ì ¹ÌºÐÈ­Çü À§¾ÏÀÌ ´Ù¹ß¼ºÀ¸·Î »ý±æ À§ÇèÀÌ ³ôÀ¸¹Ç·Î ¿¹¹æÀû À§ ÀüÀýÁ¦¼úÀ» ±Ç°íÇÑ´Ù. 2010³â International Gastric Cancer Linkage ConsortiumÀº °¡Á··ÂÀÌ ¾ø´Â 40¼¼ ¹Ì¸¸ÀÇ ¹Ì¸¸Çü À§¾Ï ȯÀÚ´Â CDH1 À¯ÀüÀÚ º¯ÀÌ °Ë»ç¸¦ ¹ÞÀ» °ÍÀ» ±Ç°íÇÏ¿´´Ù.

(3) Chief cell predominant type

À§ Á¡¸·ÀÇ oxyntic mucosa¿¡¼­ ±â¿øÇÏ´Â ºÐÈ­µµ°¡ ÁÁÀº ÀϺΠÀ§¾ÏÀº Á¶Á÷ÇÐÀûÀ¸·Î fundic gland¿Í À¯»çÇÏ¿©, Gastric adenocarcinoma of the fundic gland type-Chief cell predominant type (GA-FG-CCP) À¸·Î ºÒ¸°´Ù. ÀÌ Á¾¾çÀº mucous neck cellÀÌ chief cell·Î ºÐÈ­ÇÏ´Â ÀúÀ§µµ ºñÁ¤Çü ¼¼Æ÷ÀÇ ÇüÅÂÀÌ´Ù. ºñ±³Àû Á¡¸·ÀÇ ±âÀúºÎ¿¡¼­ ¹ß»ýÇϹǷÎ, Á¡¸·ÇÏ Á¾¾çÀÇ ÇüŸ¦ ¶ç¸é¼­ Á¡¸·Àº Á¤»ó »óÇÇÀÎ °æ¿ì°¡ ÈçÇÏ´Ù. Á¡¸·ÇÏ Á¾¾çÀÇ ÇüÅÂÀÏ °æ¿ì À§ ½Å°æ³»ºÐºñÁ¾¾ç°ú °¨º°À» ¿äÇÑ´Ù. ÆíÆòÇϰųª ÇÔ¸ôÇüÀÇ °æ¿ì ±¹¼ÒÀûÀÎ À§Ãà, ¹Ì¸¸¼º À§¾Ï, À§ ¸»Æ®Á¾°ú °¨º°À» ¿äÇÑ´Ù. ÀÌ ½Ê ¿¹ÀÇ GA-FG-CCP¸¦ ºÐ¼®ÇÑ ÀϺ» º¸°í¿¡¼­´Â ¸ðµç ¿¹°¡ À§ üºÎÀÇ º´¼ÒÀ̸ç, ´ëºÎºÐ 1cm ¹Ì¸¸ÀÇ ÀÛÀº Å©±âÀ̾ú´Ù. ÀýÁ¦ ¿¹ÀÇ 80%¿¡¼­ Á¡¸·ÇÏ Ä§À±ÀÌ Á¸ÀçÇÏ¿´À¸³ª ¸²ÇÁ°ü ħÀ±Àº ¾ø¾ú´Ù. ¶ÇÇÑ Á¾¾çÀÇ Ki-67 indexµµ ³·¾Ò´Ù. Æò±Õ 58°³¿ùÀÌ»ó °æ°ú °üÂûÇÑ ¸ðµç ¿¹¿¡¼­ ¾ÏÀÇ ÁøÇàÀº ¾ø¾ú´Ù.

3.¿ä¾à

Á¦±Õ Ä¡·á µîÀ¸·Î Ç︮ÄÚ¹ÚÅÍ °¨¿° À¯º´·üÀº Áö¼ÓÀûÀ¸·Î °¨¼ÒÇÏ°í ÀÖ°í, »ó´ëÀûÀ¸·Î HPNGC¿¡ ´ëÇÑ °ü½ÉÀº Áõ°¡ÇÒ ¼ö ÀÖ´Ù. Ç︮ÄÚ¹ÚÅÍ °¨¿°·ÂÀÌ ¾ø´Â »óŸ¦ Áø´ÜÇϱâ À§Çؼ­´Â À§ Á¡¸·ÀÇ À§Ãà Á¤µµ¸¦ ÆľÇÇÏ´Â °ÍÀÌ Áß¿äÇϸç, ÇÏüºÎ ¼Ò¸¸ÀÇ ÁýÇÕ¼¼Á¤¸ÆÀÇ ºÐÆ÷, Ç÷û Pepsinogen assay µîÀ» ÅëÇØ °´°üÀûÀ¸·Î ÆÇ´ÜÇÒ ¼ö ÀÖ´Ù. ¿ì¸®³ª¶ó¿Í ÀϺ»¿¡¼­ HPNGCÀÇ ºñÀ²Àº Àüü À§¾ÏÀÇ 1~5%°¡·®À̸ç, ¼­±¸¿¡¼­´Â À̺¸´Ù ÈξÀ ³ô´Ù. HPNGC´Â Ç︮ÄÚ¹ÚÅÍ ¾ç¼º À§¾Ï¿¡ ºñÇØ ¹ÌºÐÈ­Çü°ú À§ ±ÙÀ§ºÎ¾ÏÀÇ ºñÀ²ÀÌ ³ô´Ù. GA-FG-CCPµî Ư¡ÀûÀÎ ³»½Ã°æ ÇüŸ¦ ¼÷ÁöÇÏ¿© ±× Áø´ÜÀ²À» ³ôÀÏ ¼ö ÀÖÀ¸¸ç, À¯ÀüÀû ¹Ì¸¸Çü À§¾Ï ȯÀÚ¿¡°Ô À¯ÀüÀÚ º¯ÀÌ °Ë»ç¸¦ °í·ÁÇØ¾ß ÇÑ´Ù.



3. 2015³â Digest Endosc ¸®ºä

Helicobacter negative gastric cancer´Â ÀϺ»¿¡¼­ ²Ä²ÄÈ÷ ¿¬±¸µÇ´Â ºÐ¾ßÀÔ´Ï´Ù. Digest Endosc 2015³â 7¿ùÈ£¿¡ °ü·Ã ¸®ºä°¡ ½Ç·È½À´Ï´Ù (Yamamoto Y. Digest Endosc 2015).

Helicobacter pylori (H.pylori) leads to chronic gastritis and eventually causes gastric cancer. The prevalence of H. pylori infection is gradually decreasing with improvement of living conditions and eradication therapy. However, some reports have described cases of H. pylori-negative gastric cancers (HpNGC), and the prevalence was 0.42-5.4% of all gastric cancers. Diagnostic criteria of HpNGC vary among the different reports; thus, they have not yet been definitively established. We recommend negative findings in two or more methods that include endoscopic or pathological findings or serum pepsinogen test, and negative urease breath test or serum immunoglobulin G test and no eradication history the minimum criteria for diagnosis of HpNGC. The etiology of gastric cancers, excluding H. pylori infection, is known to be associated with several factors including lifestyle, viral infection, autoimmune disorder and germline mutations, but the main causal factor of HpNGC is still unclear. Regarding the characteristics of HpNGC, the undifferentiated type (UD-type) is more frequent than the differentiated type (D-type). The UD-type is mainly signet ring-cell carcinoma that presents as a discolored lesion in the lower or middle part of the stomach in relatively young patients. The gross type is flat or depressed. The D-type is mainly gastric adenocarcinoma of the fundic gland type that presents as a submucosal tumor-like or flat or depressed lesion in the middle and upper part of the stomach in relatively older patients. Early detection of HpNGC enables minimally invasive treatment which preserves the patient's quality of life. Endoscopists should fully understand the characteristics and endoscopic findings of HpNGC.

(1) ºñ±³Àû ÀþÀº ³ªÀÌÀÇ signet ring cell carcinoma¿Í (2) proximal stomachÀÇ flat ȤÀº SMT-likeÇÑ fundic gland type cancer°¡ Ư¡ÀûÀÎ ¼Ò°ßÀ̶ó°í ÇÕ´Ï´Ù. ¸®ºäÀÇ »çÁøÀ» ¿Å±é´Ï´Ù.

Undifferentiated-type early gastric cancer (GC). The patient was a 36-year-old man. He had no symptoms and was detected with early GC by screening endoscopy. (a,b) There was no Helicobacter pylori infection in the stomach. (c) The lesion is slightly discolored, depressed and located at the upper body greater curvature (yellow arrows). Lesion size is 11 mm. (d) He underwent endoscopic submucosal dissection, and pathological findings revealed signet ring-cell carcinoma that was limited to the mucosal layer.

Gastric cancer (GC) of fundic gland type. The patient was a 62-year-old man. He had no symptoms and was detected with early GC by screening endoscopy. (a,b) There was no Helicobacter pylori infection in the stomach. (c) The lesion is whitish, slightly depressed and located in the gastric cardia posterior wall. Dilated vessels are seen on the surface of the lesion (yellow arrows). Lesion size is 10 mm. (d) He underwent endoscopic submucosal dissection, and pathological findings revealed adenocarcinoma of the fundic gland type that was limited to the mucosal layer.


4. À̼±¿µ ±³¼ö´ÔÀÇ 2020³â ¸®ºä¿Í 2021³â °­ÀÇ


[FAQ]

[2017-8-29. ¾Öµ¶ÀÚ Áú¹®]

Ç︮ÄÚ¹ÚÅÍ À½¼º À§¾Ï¿¡ ´ëÇÑ ±Û (2017 ³»½Ã°æÇÐȸ¼¼¹Ì³ª ¼Û°æÈ£ ±³¼ö´Ô °­ÀÇ·Ï) Àß Àоú½À´Ï´Ù. Áõ·Ê´Â ¸¹Áö ¾ÊÁö¸¸ Á¦°¡ °æÇèÇÑ (1) Lymphoepithelioma-like carcinoma¿Í (2) CDH1 gene mutationÀº Èï¹Ì·Ó°Ôµµ ´ëºÎºÐÀÌ Hp ¾ç¼ºÀ¸·Î º¸°íµÇ¾î¼­ ¹®ÇåµéÀ» ã¾Æº» ÀûÀÌ ÀÖ¾ú´Âµ¥, ÀϺ»ÀÎ À§¾ÏȯÀÚÀÇ CDH1 gene mutation »ó´ç¼ö´Â Hp °¨¿°À¸·Î ÀÎÇÑ ¼Õ»óÀ¸·Î ³ªÅ¸³ª¸ç, ¼­¾ç°ú ´Þ¸® ÀϹÝÀûÀÎ ÀåÇüÀ§¾Ïó·³ ÁÁÀº °æ°ú¸¦ º¸Àδٴ ¹®ÇåÀÌ ÀÖ¾ú½À´Ï´Ù.

Á¦·Î Á¦°¡ °æÇèÇÑ CDH1 gene mutationÀ» º¸ÀÎ AGC ȯÀÚµé Áß¿¡µµ ¼ö¼ú ÈÄ 10³â °¡±îÀÌ Àç¹ß¾øÀÌ Àß Áö³»°í °è½Å ºÐµéÀÌ ÀÖ½À´Ï´Ù. ±×·¡¼­ÀÎÁö ¿ì¸®³ª¶ó¿¡¼­´Â "CDH1 gene mutationÀ» º¸ÀÎ À§¾Ï ȯÀÚ = HpÀ½¼º = ¼­¾çó·³ ¿¹ÈÄ°¡ ¸Å¿ì ³ª»Ú´Ù"¶ó°í °­ÀÇ°¡ µÇ´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ¾î¶»°Ô »ý°¢ÇϽôÂÁö¿ä?

[2017-8-30. ¼Û°æÈ£ ±³¼ö´Ô ´äº¯]

Àúµµ °æÇèÀÌ ¸¹Áö ¾Ê¾Æ ÁÁÀº ´äº¯À» µå¸±¸¸ÇÑ À§Ä¡´Â ¾Æ´Ñ °Í °°½À´Ï´Ù. HPNGC (Helicobacter negative gastric cancer)¿¡ ´ëÇÑ ¿ªÇÐ ÀڷḦ º¼ ¶§ 'Hp ¾ç¼º À§¾Ï¿¡ ºñÇØ Hp ¾ç¼ºÀ²ÀÌ ³·´Ù'·Î º¸´Â °Ô ¸Â´Ù°í »ý°¢ÇÕ´Ï´Ù. Fundic gland type GC¿¡¼­µµ Hp ¾ç¼º·üÀÌ 40-50% Á¤µµ µÇ´Â °Íó·³ ´Ù¸¥ ÇüÅÂÀÇ ¾Ï¿¡¼­µµ Hp °¨¿°Àº by-stander, ¶Ç´Â º´Àο¡ ÀÏºÎ¶óµµ °ü¿©ÇÏÁö ¾ÊÀ»±î ÃßÃøÇÕ´Ï´Ù.

Lymphoepithelioma-like carcinoma¿¡ Hp º´ÀÎÀº ¾ÆÁ÷Àº È®½ÇÄ¡ ¾ÊÀº °ÍÀ¸·Î »ý°¢ÇÕ´Ï´Ù. ¾î¶°ÇÑ ¿¬±¸¿¡¼­´Â Hp°¨¿°°ú ¿¬°ü¼ºÀÌ ¾ø°í, ¾î¶°ÇÑ ¿¬±¸´Â Hp°¨¿°°ú ¿¬°ü¼ºÀÌ ÀÖ¾ú½À´Ï´Ù. ´Ù¸¸ ¸¹Àº Áõ·Ê¿¡¼­ À§Á¡¸·À§Ãà°ú ¿¬°üÀÌ ÀÖ´Ù´Â Á¡Àä. À̸¦ º¸¸é EBV ´Üµ¶À¸·Î ¶Ç´Â Hp °¨¿°°ú ÇÔ²² º¹ÇÕÀûÀÎ ÇÁ·Î¼¼½º·Î ¹ß¾ÏÀÌ µÇ¾ú´Ù°í »ý°¢ÇÕ´Ï´Ù.

CDH1 gene mutation¿¡ ´ëÇÑ ¿¹ÈÄ´Â Á¦ °­ÀÇ¿¡¼­´Â ´Ù·çÁø ¾Ê¾Ò½À´Ù¸¸, ÀÌ°ÍÀÌ È®ÀÎµÈ È¯ÀÚµéÀº º»Àΰú ÁÖº¯ °¡Á·µé¿¡°Ô annual surveillance examÀ» °­Á¶Çϰųª, Diffuse type GC°¡ È®ÀεǾú´Ù¸é total gastrectomy¸¦ °í·ÁÇؾßÇÔÀ» °­Á¶ÇÏ¿´½À´Ï´Ù.

[2017-9-3. ÇÑ ¾Öµ¶ÀÚ ÆíÁö]

¼Û°æÈ£ ¼±»ý´ÔÀÇ ±ÍÇÑ ´äº¯ Àß Àоú½À´Ï´Ù. Çѱ¹Àο¡¼­´Â ¼ø¼öÇÑ HPNGC or lymphoepithelioma-like carcinoma´Â µå¹°°Å¶ó´Â ÀÇ°ß¿¡´Â µ¿ÀÇÇÕ´Ï´Ù. ´Ù¸¸ CDH1 gene mutation ȯÀÚ º»Àΰú ÁÖº¯ °¡Á·µé¿¡°Ô annual surveillance examÀ» °­Á¶Çϰųª, Diffuse type GC°¡ È®ÀεǾú´Ù¸é total gastrectomy¸¦ °í·ÁÇØ¾ß ÇÑ´Ù´Â ÀÇ°ß¿¡´Â ¹Ý´ëÇÕ´Ï´Ù. ¿Ö³ÄÇϸé Çѱ¹ÀÎ À§¾Ï ȯÀÚµéÀº Hp °¨¿°À¸·Î ÀÎÇÑ CDH1 hypermethylationÀÌ ÈçÇؼ­, ¼­¾ç¿¡¼­ ¹ß°ßµÇ´Â CDH1 gene mutation ÀÚü·Î ÀÎÇÑ ¼ø¼öÇÑ familial diffuse-type GC¿Í º»ÁúÀûÀ¸·Î ´Ù¸£±â ¶§¹®ÀÔ´Ï´Ù.

ÇöÀç ±¹³»´ëÇк´¿ø¿¡¼­´Â À§¾Ï¼ö¼ú ÈÄ¿¡ CDH1 º¯ÀÌ ¿©ºÎ¸¦ e-cadherin ¸é¿ª¿°»ö °á°ú·Î ÆÇ´ÜÇÏ¿© Á¦½ÃÇÏ°í Àֱ⠶§¹®¿¡, CDH1 º¯ÀÌ°¡ ÀÖ´Ù°í ³ª¿Íµµ ±»ÀÌ ÁÖº¯ °¡Á·µé¿¡°Ô ÀÌ ¶§¹®¿¡ annual surveillance examÀ» °­Á¶ÇÒ ÇÊ¿ä´Â ¾øÀ¸¸ç, ¼³»ç diffuse type GC°¡ È®ÀεǾú´õ¶óµµ ÀÌ ¶§¹®¿¡ total gastrectomy¸¦ ±ÇÇÒ ÇÊ¿ä´Â ¾ø´Ù´Â °ÍÀÌ Á¦ »ý°¢ÀÔ´Ï´Ù.


[2021-9-3. InterMD ³»½Ã°æ ¼¼¹Ì³ª Áú¹®]

À̼±¿µ ±³¼ö´ÔÀÇ 2020³â ¸®ºä¸¦ Àß º¸¾Ò½À´Ï´Ù. Helicobacter À½¼º signet ring cell carcinoma´Â 'À¯¹®¼±¿Í À§Àú¼±ÀÇ °æ°è¼±'¿¡¼­ ¹ß»ýÇÑ´Ù°í µÇ¾î Àִµ¥ ±¸Ã¼ÀûÀÎ À§Ä¡´Â ¾îµðÀԴϱî?

[2021-9-3. ÀÌÁØÇà ´äº¯]

¾Æ·¡ ±×¸²À» Âü°íÇϽñ⠹ٶø´Ï´Ù. À¯¹®¼±°ú À§Àú¼±ÀÇ °æ°è´Â À§Ã¼ÇÏºÎ¿Í ±ÙÀ§ÀüÁ¤ºÎ »çÀÌ Á¤µµÀÔ´Ï´Ù.


[References]

1) EndoTODAY Ç︮ÄÚ¹ÚÅÍ

2) [Review] Hp À½¼º À§¾Ï (À̼±¿µ 2020)

3) ÀÚ°¡¸é¿ª¼º ¸¸¼º À§Ã༺ À§¿°°ú ¿¬°üÇÏ¿© ¹ß»ýÇÑ À§ ½Å°æ³»ºÐºñÁ¾¾ç Neuroendocrine tumor associated with autoimmune gastritis (´ëÇѼÒÈ­±â³»½Ã°æÇÐȸ 2021-8 ±³À°ÀÚ·á)

© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng. (since 1999-8-23)